Economic Evaluation of Health Care
|
|
- Bernadette Lester
- 5 years ago
- Views:
Transcription
1 Economic Evaluation of Health Care (Evaluasi Ekonomi untuk Pelayanan Kesehatan) Getting the best value for health spending Prof. dr. Bhisma Murti, MPH, MSC, PhD Institute of Health Economic and Policy Studies (IHEPS), Department of Public Health, Faculty of Medicine, Universitas Sebelas Maret
2 What is Economic Evaluation? Economic evaluation is the comparative analysis of alternative courses of action in terms of both their costs and consequences Cost (resources, inputs A,B,C) Health care (intervention or program A,B,C) Consequence (benefit, utility, outcome, effect A,B,C)
3 Non-health care The Rationale for Economic Evaluation in Health Care Resources are scarce (budget constraint, limited number of health care staff, lack of medicine, etc.) so they must be used efficiently and equitable Clinical decision making has cost implication to patient, insurance company, and government that pay for the health care provided Economic evaluation provides a scientific tool for selecting the most costeffective health intervention Health care Budget constraint Budget relaxed
4 How Do We Do Economic Evaluation? Competing alternatives (saling bersaing) Limited budget Intervention A? Intervention B? Intervention C? Decision rule: Choose the most costeffective intervention (the best value for limited budget) Cost-effective intervention Budget Population health
5 Technical Efficiency (Efisiensi Teknis) Produce the same level of output with less cost or higher level of output with the same cost (cost-efficiency) Intervention A costs Rp 100,000,000 Choose Intervention B costs Rp 200,000,000 Choose intervention A because it costs less to produce the same level of output as intervention B
6 Non-health programs Allocative Efficiency (Efisiensi Alokatif) Resources are allocated such that community welfare at large is maximized Allocative efficiency can be achieved if all parties across sectors produce efficiently Allocatively efficient because resources allocated meet the highest utility to the community) Health programs Utility (welfare) to the community at large Allocatively inefficient (too much health program)
7 Types of Economic Evaluation Types of economic evaluation: 1. Cost-effectiveness analysis (CEA) Cost-Minimization Analysis (CMA) 2. Cost-utility analysis (CUA) 3. Cost-benefit analysis (CBA) Full economic evaluation compares both costs and consequences of two or more alternatives (Drummond et al. 2005)
8 Cost-Effectiveness Analysis Compares alternative interventions where costs are measured in monetary term and benefits in natural units: Number of patients showing better clinical outcome Number of infants immunized (note: both the above examples refer to an immediate outcome of health care intervention) Number of child death averted Years of life gained, etc. Can be used to address technical efficiency Where the level of health benefits of all alternatives are equal, so only costs of the alternatives to be compared, this CEA is called Cost-Minimization Analysis (CMA)
9 Cost-Utility Analysis Compare alternative interventions where health benefits are measured in QALYs, DALYs, HYEs, HALYs, etc Quality-Adjusted Life Year (QALYs) are valued on a utility (U) index where U=1 represents perfect health and U=0 represents death Example of QALYs: 5 years of perfect health = 5 QALYs 3 years of perfect health followed by 2 years in a state valued to be 0.8 of perfect health= (3 years x 1U) + (2 years x 0.8U) = 4.6 QALYs Can address both technical efficiency and allocative efficiency
10 What is QALY? Quality-adjusted life year (QALY) is a measure of health benefit or health state that combines the quantity and quality of life Quality of life 1 Improved quality of life with program QALY without program Improved quantity of life with program 0 Time
11 Cost-Benefit Analysis Comparing alternatives where both costs and benefits are measured in monetary terms Valuation method of health benefits: 1. Human capital approach 2. Willingness to pay (WTP) Can compare two or more interventions across different sectors (e.g., health, education, transportation) according to their net effects on community welfare Can address allocative efficiency Costs Health benefits
12 Basic Model of Decision Making Program A Probability A Consequences CHOICE Consequence A Program B Probability B Consequences An economic evaluation can be performed within the context of an experiment or other studies, a simulation model, or their combination Consequence B
13 Decision Rule Choose alternative intervention with lower C/E Ratio (CER) CER+ CER++++ Choose Intervention A
14 CEA for Independent Interventions For example: Oral Rehydration Therapy and Immunization are independent programs, each aims to avert child mortality For independent intervention, calculate the cost-effectiveness ratios (CERs): CER= C/E C= cost of intervention E= effectiveness of intervention CER of each intervention implies comparison with do-nothing alternative Draw a table comparing the alternatives List the alternatives from the most effective to the least effective one Compare the CERS, select the most cost-effective alternative
15 CEA for Mutually Exclusive Interventions For example: current immunization program and immunization plus nutrition program are mutually exclusive. Added nutrition element is called incremental. For mutually exclusive programs, calculate the incremental costeffectiveness ratio (ICER): ICER= (C1 C2) / (E1 - E2) C1= cost of program 1 C2= cost of program 2 E1= effectiveness of program 1 E2= effectiveness of program 2 Draw a table comparing the alternatives List the alternatives from the least effective to the most effective one Compare the ICERS, exclude the dominated alternative Redraw a new table until 2 alternatives left
16 Cost difference (ΔC), How To Compare and Choose the More Cost-Effective One among Alternative Interventions New intervention more costly, less effective ( Excluded ) New intervention less costly, but also less effective ( Questionable ) Current Intervention New intervention more costly, more effective ( Cost-effective ) New intervention less costly, more effective ( Dominance ) Effectiveness difference (ΔE) Cost-effectiveness plane demarcates acceptable ICER Alternative with ICER below and to the right of the plane are likely to be acceptable. *Bell et al., 2006
17 Summary (Ringkasan) Resources are scarce, so they must be used efficiently and equitably Economic evaluation provides a scientific tool for clinicians and health planners to choose the most efficient health intervention to attain the highest possible health status of the patient and community
18
Efficiency: Concepts and Methods. Hui Ru Chang Department of Medical Affairs, Mackay Memorial Hospital May 25, 2010
Efficiency: Concepts and Methods Hui Ru Chang Department of Medical Affairs, Mackay Memorial Hospital May 25, 2010 1 Contents 2 What is Efficiency? Methods of Assessing Efficiency Cost Effectiveness Analysis
More informationASAP Regional Training on Epidemiological and Economic Tools for HIV/AIDS Strategic Planning S P ECONOMIC EVALUATION IN HEALTH CARE
ASAP Regional Training on Epidemiological and Economic Tools for HIV/AIDS Strategic Planning ECONOMIC EVALUATION IN HEALTH CARE Outline of the Session 1. What is Economic Evaluation? 2. Why do Economic
More informationASAP Regional Training on Epidemiological and Economic Tools for HIV/AIDS Strategic Planning S P ECONOMIC EVALUATION IN HEALTH CARE
ASAP Regional Training on Epidemiological and Economic Tools for HIV/AIDS Strategic Planning ECONOMIC EVALUATION IN HEALTH CARE Outline of the Session 1. What is Economic Evaluation? 2. Why do Economic
More informationIntroduction of Health Economics
Introduction of Health Economics Prof. Jie Chen Health Technology Assessment & Research Center Fu Dan University 4 th March, 2004 Outline Why economics for healthcare services? Some basic economic concepts
More informationCost-Effectiveness Analysis: The Bare Essentials
Cost-Effectiveness Analysis: The Bare Essentials Michael K. Gould, MD, MS Director for Health Services Research and Implementation Science Department of Research and Evaluation Kaiser Permanente Southern
More informationModelling and Health Economics
EACS HIV Summer School 2018 Modelling and Health Economics Valentina Cambiano UCL Institute of Global Health 1 st September 2018 Conflict of Interests No conflict of interests to declare. 2 Outline What
More informationEconomic Evaluations in Health An introduction for clinicians, researchers, and policy makers
Economic Evaluations in Health An introduction for clinicians, researchers, and policy makers Philip Leonard, PhD, MSSU and UNB Economics May 16, 2016 Saint John Regional Hospital, NB Economics in health
More informationStep by step guide to economic evaluation in cancer trials
What is CREST? The Centre for Health Economics Research and Evaluation (CHERE) at UTS has been contracted by Cancer Australia to establish a dedicated Cancer Research Economics Support Team (CREST) to
More informationOverview of Pharmaco- Economics Methodologies Maher Hassoun, M.S.
Overview of Pharmaco- Economics Methodologies Maher Hassoun, M.S. Director of Communications, ISPOR Lebanon Chapter (LSPOR) ISPOR Member Country Manager, Mundipharma Lebanon and Jordan Outline Current
More informationIncorporating Economic Evaluation in Clinical & Translation Research. Setting expectations. Why bother with economic evaluation? Introduction 10/9/17
Incorporating Economic Evaluation in Clinical & Translation Research Fernando A. Wilson, PhD Health Services Research & Administration College of Public Health University of Nebraska Medical Center Setting
More informationIntroduction to key concepts and definitions
Introduction to key concepts and definitions Presenter: Marcia Weaver, PhD Research Associate Professor International Training and Education Center for Health (ITECH) Department of Global Health University
More informationIs the QALY a Necessary Evil? Michael Drummond Centre for Health Economics, University of York
Is the QALY a Necessary Evil? Michael Drummond Centre for Health Economics, University of York Outline of Presentation Some background. What s good about the QALY? What adjustments are required to QALYs?
More informationEconomic evaluations are defined as the comparative analysis of alternative
Nyman Economic Evaluations in Healthcare: Overview, Policy, and Uses John A. Nyman, PhD Overview: The Basics Economic evaluations are defined as the comparative analysis of alternative courses of action
More informationEconomics Concepts Overview
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationDecision Rules. Kevin Frick, PhD. Johns Hopkins University
Decision Rules Kevin Frick, PhD Johns Hopkins University Decision Rules for Cost-Benefit Analysis Section A Variations on Decision Rules Covered in this session Non-budget constrained CBA Budget constrained
More informationAN OVERVIEW OF PHARMACOECONOMICS AND OUTCOMES RESEARCH
Int. J. LifeSc. Bt & Pharm. Res. 2012 Harika Javangula, 2012 Review Article ISSN XXXX-XXXX www.ijlbpr.com Vol.1, Issue. 1, January 2012 2012 IJLBPR. All Rights Reserved AN OVERVIEW OF PHARMACOECONOMICS
More informationIntroduction to Pharmacoeconomics. Almut G. Winterstein, Ph.D.
Introduction to Pharmacoeconomics Almut G. Winterstein, Ph.D. Why do we need Health Economics? Suppose you are comparing two drugs or services where one is more expensive than the other. In choosing the
More informationIntroduction to Economic Evaluation. AEA/CDC Summer Evaluation Institute 2011
Introduction to Economic Evaluation AEA/CDC Summer Evaluation Institute 2011 Outline Overview of economic evaluation methods Basics of measuring program costs Measuring outcomes for use in economic evaluations
More information{ } Sample Size and Power for the Comparison of Cost and Effect. Goal of Sample Size Calculation. Sample Size Formula, Common SDs.
Sample Size and Power for the Comparison of Cost and Effect Henry Glick Applications of Statistical Considerations in Health Economic Evaluations ISPOR 13 th International Meeting May 4, 2008 Goal of Sample
More informationEconomic Evaluation: Making the case for diabetes selfmanagement
Economic Evaluation: Making the case for diabetes selfmanagement education NACDD Webinar Series Session 2: Applying Economic Evaluation October 4, 2012 Carsten Baumann, MA DSME Webinar Series Blueprint
More informationNOVEL APROACHES TO VALUE: BEYOND COST EFFECTIVENESS. Novel Approaches to Value Assessment, Beyond Cost- Effectiveness Framework
Novel Approaches to Value Assessment, Beyond Cost- Effectiveness Framework Charles Phelps, PhD University of Rochester Rochester, NY, USA NOVEL APROACHES TO VALUE: BEYOND COST EFFECTIVENESS Charles E.
More informationRecommendations of the Panel on Cost- Effectiveness in Health and Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationHealth Economics Workshop: Costing Tools. Monisha Sharma, PhD International Clinical Research Center (ICRC) University of Washington
Health Economics Workshop: Costing Tools Monisha Sharma, PhD International Clinical Research Center (ICRC) University of Washington Reminder: uses of cost data Priority setting for new interventions or
More informationGates Reference Case: background, structure and content
Gates Reference Case: background, structure and content Tommy Wilkinson Advisor (Health Economics) NICE International NICE copyright 2014 2 1 Methods for Economic Evaluation Project (MEEP) Led by NICE
More informationEconomic Evaluation Abstraction Form Version 4.0 (last update: June 2010)
Economic Evaluation Abstraction Form Version 4.0 (last update: June 2010) Introduction This economic abstraction form is used for the Guide to Community Preventive Services (the Community Guide) to systematically
More informationIntroduction to Health Economics. Educational Seminar ISPOR Dubai - September 19, 2018
Introduction to Health Economics Educational Seminar ISPOR Dubai - September 19, 2018 Introduction to health economics Part 1 Nancy Devlin Director of Research, Office of Health Economics, London ISPOR
More informationEvaluating the value of new drugs
Evaluating the value of new drugs The ICER value framework The framework includes Content A list of elements to consider Measurement options Methods to measure or judge each element Assessment process
More informationECONOMIC ANALYSIS IN HEALTH CARE
ECONOMIC ANALYSIS IN HEALTH CARE Second Edition Stephen Morris Nancy Devlin David Parkin and Anne Spencer WILEY A John Wiley and Sons, Ltd, Publication Preface xiii Chapter 1 Introduction to economic analysis
More informationECONOMIC VALUE OF VACCINES
ECONOMIC VALUE OF VACCINES ISPOR Forum of the Economic Value Assessment of Vaccines Designed to Prevent Infectious Disease Task Force Monday, May 23, 2016 Outline for the Forum Task Force Leadership Group
More informationHSPM 818: Economic Evaluation and Policy Analysis of Health Services. Fall Semester 2011, Week 1: Introduction Assistant Professor Brian Chen
HSPM 818: Economic Evaluation and Policy Analysis of Health Services Fall Semester 2011, Week 1: Introduction Assistant Professor Brian Chen Introductions Course description Course objective Assignments
More informationHTA and Submissions. Ferg Mills, Angela Rocchi April 5, Agenda
HTA and Submissions Ferg Mills, Angela Rocchi April 5, 2017 Agenda The Decision Problem Role of HTA bodies in Canada CADTH, pcodr and INESSS Overview of the elements of the HTA submission Clinical package
More informationThe ICER Value Framework: The Importance of Empirical Estimates of Opportunity Costs
The ICER Value Framework: The Importance of Empirical Estimates of Opportunity Costs Steven D. Pearson, MD, MSc The ICER Value Framework Takes a population level perspective as opposed to trying to serve
More informationLuciana Scalone. Centro di Farmacoeconomia Università degli Studi di Milano. Problem
Qualità della Vita Legata allo Stato di Salute in Farmacoeconomia Luciana Scalone Centro di Farmacoeconomia Università degli Studi di Milano Problem Needs are unlimited resources are limited Resources
More informationPOLISH GUIDELINES FOR CONDUCTING PHARMACOECONOMIC EVALUATIONS. (project)
POLISH GUIDELINES FOR CONDUCTING PHARMACOECONOMIC EVALUATIONS Ewa Orlewska 1, Piotr Mierzejewski 1,2 (project) 1 Department of Experimental and Clinical Pharmacology, Medical University of Warsaw Head
More informationWhat can Health Economics do for you?
Incorporating Health Economics into Grant Proposals Health Economics Short Course For more information and course dates, please visit our website: http://go.unimelb.edu.au/i8ba Or email us: health-economics@unimelb.edu.au
More informationQualità della Vita Legata allo Stato di Salute in Farmacoeconomia
Qualità della Vita Legata allo Stato di Salute in Farmacoeconomia Luciana Scalone, PharmD, DSc Centro di Farmacoeconomia Università degli Studi di Milano Problem Needs are unlimited resources are limited
More informationLARC: Return on Investment Virtual Learning Session. August 2, :00-4:00p ET For Audio: , ext #
LARC: Return on Investment Virtual Learning Session August 2, 2016 2:00-4:00p ET For Audio: 866-740-1260, ext. 5273187# Agenda 2:00 Welcome and Introductions 2:10 Basics of Economic Analysis and Return
More informationPROJECT CRITERIA: ECONOMIC VIABILITY AND PROJECT ALTERNATIVES
SESSION 1.2 PROJECT CRITERIA: ECONOMIC VIABILITY AND PROJECT ALTERNATIVES Introductory Course on Economic Analysis of Investment Projects Economics and Research Department (ERD) Discounted Cash Flow: Measures
More informationA framework for measuring the impact of HTA policy interventions. Eleanor Grieve University of Glasgow July 2015
A framework for measuring the impact of HTA policy interventions Eleanor Grieve University of Glasgow July 2015 A methodological framework for measuring the impact of HTA policy interventions a review
More informationGuidelines for cost and cost-effectiveness analysis of tuberculosis control DOCUMENT
Guidelines for cost and cost-effectiveness analysis of tuberculosis control DOCUMENT 1 INTRODUCTION, IMPORTANT ECONOMIC CONCEPTS, PROTOCOLS, AND USEFUL REFERENCES GUIDELINES FOR COST AND COST-EFFECTIVENESS
More informationRe-thinking cost per QALYs in drug reimbursement decision making
Re-thinking cost per QALYs in drug reimbursement decision making Craig Mitton, PhD Professor and Senior Scientist Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute
More informationFEEDBACK ON ECONOMIC MODELS FROM THE PAN-CANADIAN ONCOLOGY DRUG REVIEW (PCODR) EXPERT COMMITTEE: AN UPDATE
FEEDBACK ON ECONOMIC MODELS FROM THE PAN-CANADIAN ONCOLOGY DRUG REVIEW (PCODR) EXPERT COMMITTEE: AN UPDATE 2017 CADTH Symposium Ottawa, ON April 23-25 Kelly Qiao Qu, MSc Amaris, Toronto, Canada Rebecca
More informationDECISION RULES. Lecture 11. Kevin Frick
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationBayesian Analysis: Bayesian Analysis in Health Economics Bayesian Analysis: Posterior Interval Bayesian Analysis: Prior Distribution
Bayesian Analysis Bayesian Analysis Bayesian Analysis Bayesian Analysis Biotechnology Biotechnology Biotechnology Bootstrapping Case Mix Index Clinical Practice Guidelines Study Bias Study Bias Study Bias
More informationSearching for the social value of a QALY in the Netherlands: The Willingness to Pay for a QALY
Searching for the social value of a QALY in the Netherlands: The Willingness to Pay for a QALY Name: Maja Obradovic Student number: 295113 Project: Master Thesis Health Economics Tutor: A. Bobinac, PhD
More informationSession 2.2 Project Alternatives, Least Cost and Cost Effectiveness Analyses
Session 2.2 Project Alternatives, Least Cost and Cost Effectiveness Analyses Introductory Course on Economic Analysis of Investment Projects 30 June 2009 Cost Effectiveness Analysis - 1 An appraisal and
More informationResults Based Financing for Health Impact Evaluation Workshop Tunis, Tunisia October Evaluating the Cost and Financial Impact of RBF Schemes
Results Based Financing for Health Impact Evaluation Workshop Tunis, Tunisia October 2010 Evaluating the Cost and Financial Impact of RBF Schemes Logan Brenzel, PhD Why consider cost and financial analysis
More informationA decision-analytic approach for supporting healthcare resource allocation
A decision-analytic approach for supporting healthcare resource allocation, Yrjänä Hynninen, and Ahti Salo Aalto University School of Business, Department of Information and Service Economy Aalti University
More informationGuidelines for the Budget Impact Analysis of Health Technologies in Ireland
Guidelines for the Budget Impact Analysis of Health Technologies in Ireland 2014 1 About the Health Information and Quality Authority The (HIQA) is the independent Authority established to drive continuous
More informationMethodology to assess the cost impact of PMB benefit definitions
Methodology to assess the cost impact of PMB benefit definitions Version 1.0.0 07 March 2012 Contents 1 Background... 1 2 Aim... 1 3 Objectives... 1 4 Methods... 2 5 Variables for data collection, data
More informationICER Value Assessment Framework: 1.0 to 2.0
ICER Value Assessment Framework: 1.0 to 2.0 Outline Background on ICER Version 1.0 development Conceptual basis for ICER value assessment framework Domains of value Long-term perspective (value for money)
More informationUNICEF s equity approach: from the 2010 Narrowing the Gaps study via equity focused programming and monitoring to a Narrowing the Gaps+5 study &
UNICEF s equity approach: from the 2010 Narrowing the Gaps study via equity focused programming and monitoring to a Narrowing the Gaps+5 study & EQUIST Narrowing the Gaps: Right in Principle, Right in
More informationGuidelines for the Budget Impact Analysis of Health Technologies in Ireland
Authority Guidelines for the Budget Impact Analysis of Health Technologies in Ireland Health Information and Quality Guidelines for the Budget Impact Analysis of Health Technologies in Ireland 2018 1 2
More informationMaking the Case for Public Health: Estimating ROI and Value
University of Kentucky UKnowledge Health Management and Policy Presentations Health Management and Policy 7-18-2012 Making the Case for Public Health: Estimating ROI and Value Glen P. Mays University of
More informationThe (Near) Equivalence of Cost-Effectiveness and Cost-Benefit Analyses Fact or Fallacy?
CURRENT OPINION Pharmacoeconomics 1998 Apr; 13 (4): 389-396 1170-7690/98/0005-0389/$04.00/0 Adis International Limited. All rights reserved. The (Near) Equivalence of Cost-Effectiveness and Cost-Benefit
More informationProbabilistic Sensitivity Analysis Prof. Tony O Hagan
Bayesian Methods in Health Economics Part : Probabilistic Sensitivity Analysis Course outline Part : Bayesian principles Part : Prior distributions Part 3: Uncertainty in health economic evaluation Part
More informationEconomic Evaluation of Healthcare Programmes and Interventions in Low and Middle Income Countries: Directions for Future Methods Research
Economic Evaluation of Healthcare Programmes and Interventions in Low and Middle Income Countries: Directions for Future Methods Research Paul Revill 1, Beth Woods 1, Mark J. Sculpher 1 1. Centre for Health
More informationCost-effectiveness analysis: Balancing value with affordability?
AMCP Webinar Cost-effectiveness analysis: Balancing value with affordability? Michael Drummond, Dan Danielson and Steven D. Pearson MODERATOR: Michael Drummond, PhD University of York UK 1 Cost-Effectiveness
More informationUsing Household Production Models to Understand Environmental Health Outcomes in Developing Countries
International Journal of Behavioral Science KARNJANA SANGLIMSUWAN Copyright 2012 by Behavioral Science Research Institute 2012, Vol. 7, No.1, 99-108 ISSN: 1906-4675 Using Household Production Models to
More informationrff report Valuing Health Outcomes: Policy Choices and Technical Issues Executive Summary Alan J. Krupnick MARCH 2004
rff report MARCH 2004 Valuing Health Outcomes: Policy Choices and Technical Issues Executive Summary Alan J. Krupnick MISSION Resources for the Future improves environmental and natural resource policymaking
More informationEffect of costing methods on unit cost of hospital medical services; A case of capital cost
Original Article Mahidol Univ J Pharm Sci 2016; 43 (2), 97-105 Effect of costing methods on unit cost of hospital medical services; A case of capital cost A. Riewpaiboon 1*, S. Rajbhandari 1, P. C. Coyte
More informationGYÓGYSZEREINK SPECIAL ISSUE PROFESSIONAL HEALTHCARE GUIDELINE ON THE METHODOLOGY OF HEALTH TECHNOLOGY ASSESSMENT
Fókusz / Júliustól új elvek mentén, GYÓGYSZEREINK PUBLICATION OF THE NATIONAL INSTITUTE OF PHARMACY AND NUTRITION WWW.OGYEI.GOV.HU Volume 67, Issue 1, 2017 SPECIAL ISSUE PROFESSIONAL HEALTHCARE GUIDELINE
More informationScaling up interventions in the Eastern Mediterranean Region. What does it take and how many lives can be saved?
Scaling up interventions in the Eastern Mediterranean Region What does it take and how many lives can be saved? Introduction Many elements influence a country s ability to extend health service delivery
More informationWhat does the Value of Modern Medicine Say About
What does the Value of Modern Medicine Say About the $50,000/QALY Threshold? Duke/NUS Singapore September 5, 2016 Mark S. Roberts, MD, MPP Professor and Chair, Department of Health Policy and Management
More informationHealth analytics for informed decision-making
Health analytics for informed decision-making Assistant Professor of Management Science Aalto University School of Business, Department of Information and Service Economy Decision making in healthcare
More informationNATIONAL POLICY IN HEALTH FINANCING
NATIONAL POLICY IN HEALTH FINANCING 5 th Congress Indonesia Health Economics Association ( InaHea) Jakarta, 31 st Oct 2018 PRESENTATION OUTLINE Introduction Overview of Indonesia s Health Financing Evaluation
More informationProbabilistic Sensitivity Analysis and Value of Information in Cost-Effectiveness Models
Probabilistic Sensitivity Analysis and Value of Information in Cost-Effectiveness Models Richard Nixon Novartis Pharma AG June 12 th, 2014 Summary One step parameter estimation and cost-effectiveness model
More informationIntroduction to Decision Analysis
Introduction to Decision Analysis M.Sc. (Tech) Yrjänä Hynninen Dept of Mathematics and Systems Analysis Analytics and Data Science seminar, October 16, 2017 Learning objectives Develop an understanding
More informationGuidelines for the Budget Impact Analysis of Health Technologies in Ireland
Guidelines for the Budget Impact Analysis of Health Technologies in Ireland 2010 1 About the The is the independent Authority which has been established to drive continuous improvement in Ireland s health
More informationHealth Economics 3. Competition in Health Care Evaluation of Health & Life
Health Economics 3 Competition in Health Care Evaluation of Health & Life Trends in Health Organization Health services were historically established as private, charitable, religious, or governmental
More informationDeposited on: 12 May 2008 Glasgow eprints Service
Fenwick, E. and Claxton, K. and Sculpher, M. (2008) The value of implementation and the value of information: combined and uneven development. Medical Decision Making 28(1):pp. 21-32. http://eprints.gla.ac.uk/4172/
More informationFrameworks to Set Priorities for Treatments Based on Cost-Effectiveness and Equity
The Open Pharmacoeconomics & Health Economics Journal, 2012, 4, 1-7 1 Open Access Frameworks to Set Priorities for Treatments Based on Cost-Effectiveness and Equity Pedro Plans-Rubió * Public Health Agency
More informationValuing Health Outcomes
Valuing Health Outcomes Prepared by: Lisa A. Robinson Harvard T.H. Chan School of Public Health Center for Risk Analysis and Center for Health Decision Science Prepared for: Scoping Workshop Bill and Melinda
More informationUsing the OneHealth tool for planning and costing a national disease control programme
HIV TB Malaria Immunization WASH Reproductive Health Nutrition Child Health NCDs Using the OneHealth tool for planning and costing a national disease control programme Inter Agency Working Group on Costing
More informationCriteria and Guidelines for the Analysis of Long-Term Impacts on Healthcare Costs and Public Health California Health Benefits Review Program
Criteria and Guidelines for the Analysis of Long-Term Impacts on Healthcare Costs and Public Health California Health Benefits Review Program The California Health Benefits Review Program (CHBRP) must
More informationThe determinants of change in the cost-effectiveness threshold
The determinants of change in the cost-effectiveness threshold [PWP 2015_01] Mike Paulden, MSc 1, James O Mahony, PhD 2, and Christopher McCabe, PhD 1 1 Department of Emergency Medicine, University of
More information(A) Is it Worth the Money? And (B) Can We Afford it? Assessing the Value of Prescription Drugs
(A) Is it Worth the Money? And (B) Can We Afford it? Assessing the Value of Prescription Drugs Dan Ollendorf, PhD Chief Scientific Officer Institute for Clinical and Economic Review August 9th, 2016 Disclosure
More informationEvaluating the Value of New Drugs and Devices
Evaluating the Value of New Drugs and Devices Copyright ICER 2015 The ICER Value Framework The problems the value framework was intended to address Poor reliability and consistency of value determinations
More informationAccounting for the Timing of Costs and Benefits in the Evaluation of Health Projects Relevant to LMICs Karl Claxton
Accounting for the Timing of Costs and Benefits in the Evaluation of Health Projects Relevant to LMICs Karl Claxton October 2017 Review Draft Guidelines for Benefit Cost Analysis Working Paper No. 8 Prepared
More informationModelling the Cost Effectiveness of Interventions, Strategies, Programmes and Policies to reduce the number of employees on sickness absence
Revised modelling report Modelling the Cost Effectiveness of Interventions, Strategies, Programmes and Policies to reduce the number of employees on sickness absence Revised Report October 2008 Modelling
More informationDo Novel Value Measures Have a Place in European HTA?: A U.S. Health Economist Perspective
Do Novel Value Measures Have a Place in European HTA?: A U.S. Health Economist Perspective ISPOR-EU panel presentation, Monday Nov 12, 2018, 3.45-4.45pm [Breakout Session #2 (IP6)] November 12, 2018 Barcelona
More informationDecision Analysis to Guide Policy on the Introduction of a Routine Second Dose of Measles Vaccine
Decision Analysis to Guide Policy on the Introduction of a Routine Second Dose of Measles Vaccine by Ann Levin and Colleen Burgess (MathEcology, LLC) 29/01/2009 WHO-SAGE Meeting, Geneva 1 Indian States
More informationThe following box outlines the basic steps in economic analysis. The last
4 The Groundwork for Economic Analysis 11 The following box outlines the basic steps in economic analysis. The last three are often given most attention in how to guidelines and this is understandable
More informationEconomics 317 Health Economics III Sample questions for midterm examination I February, 2011
University of Victoria Department of Economics Economics 317 Health Economics III Sample questions for midterm examination I February, 2011 1 Multiple guess questions. 1. The RAND Health Insurance Experiment
More informationCOSTING INTERVENTIONS
ASAP Regional Training on Epidemiological and Economic Tools for HIV/AIDS Strategic Planning COSTING INTERVENTIONS Julian Naidoo (Ph.D) Durban, November 2007 STRATEGY RESULTS CYCLE Formulate/Revise HIV/AIDS
More informationCost-Benefit Analysis in the study of the effectiveness of health programs
Cost-Benefit Analysis in the study of the effectiveness of health programs Jadwiga Suchecka, Maciej Jewczak Abstract Ensuring proper access to health services is a critical problem faced by contemporary
More informationHealthcare Cost Increases: Can They Be Managed Effectively?
Healthcare Cost Increases: Can They Be Managed Effectively? Actuarial Society of Hong Kong Evening Talk February 24, 2006 Howard J. Bolnick, FSA, MAAA, HonFIA Chairman, IAA Health Section Adjunct Professor
More informationTHE FIRM AND ITS GOALS. Dr. Mohammed Alwosabi
CHAPTER TWO THE FIRM AND ITS GOALS Dr. Mohammed Alwosabi 1 The Firm The firm is an organization, which brings resources together to produce a good or service that is demanded in the market. The firm bears
More informationOn the Margins of Health Economics: Searchers, Surveyors and the Monetary Value of a Qaly
CHEPA WORKING PAPER SERIES Paper 14-01 On the Margins of Health Economics: Searchers, Surveyors and the Monetary Value of a Qaly March 13, 2014 Stephen Birch, D.Phil. a,b Amiram Gafni, Ph.D. b a Centre
More informationDying Too Soon. How Cost-Effectiveness Analysis Can Save Lives TAMMY O. TENGS
Dying Too Soon How Cost-Effectiveness Analysis Can Save Lives TAMMY O. TENGS For every one of us, death is inevitable. Premature death, however, is not. Through some reasonable mix of public and private
More informationGlenn P. Jenkins Queen s University, Kingston, Canada and Eastern Mediterranean University, North Cyprus
COST-BENEFIT ANALYSIS FOR INVESTMENT DECISIONS, CHAPTER 15: COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS Glenn P. Jenkins Queen s University, Kingston, Canada and Eastern Mediterranean University, North
More informationIn our model this theory is supported since: p t = 1 v t
Using the budget constraint and the indifference curves, we can find the monetary. Stationary equilibria may not be the only monetary equilibria, there may be more complicated non-stationary equilibria.
More informationAdvanced Analytics. The key to unlocking the Triple Aim and Value-Based Purchasing. Ines Vigil MD, MPH, MBA
Advanced Analytics The key to unlocking the Triple Aim and Value-Based Purchasing Ines Vigil MD, MPH, MBA Advanced Analytics: The key to unlocking the Triple Aim and Value-Based Purchasing Current State
More informationPricing developments in the Asia Pacific does comparatorreferenced
Pricing developments in the Asia Pacific does comparatorreferenced pricing have a future? Educational Symposium: Monday 5 th September 2016 ISPOR AsiaPacific conference, Singapore MODERATOR: Adèle Weston
More informationRobert Moss, PhD Professor of Biology, and Health Careers Advisor
Robert Moss, PhD Professor of Biology, and Health Careers Advisor Wofford College *Presentations will be available at http://webs.wofford.edu/mossre/hcreform.htm Why are we here? Copyright 2009 Creators
More informationThe Lagrangian method is one way to solve constrained maximization problems.
LECTURE 4: CONSTRAINED OPTIMIZATION QUESTIONS AND PROBLEMS True/False Questions The Lagrangian method is one way to solve constrained maximization problems. The substitution method is a way to avoid using
More informationOne-way sensitivity analysis for stochastic cost effectiveness analysis: conditional expected incremental net benefit [PWP 2017_01]
One-way sensitivity analysis for stochastic cost effectiveness analysis: conditional expected incremental net benefit [PWP 2017_01] Christopher McCabe MSc. PhD. And Isaac Awotwe Msc. Mike Paulden MSc.
More informationQuality of Health Care and the Design of the Basic Benefit Package Lessons from Overseas
Quality of Health Care and the Design of the Basic Benefit Package Lessons from Overseas Michael Drummond Centre for Health Economics, University of York Outline of Presentation Efficiency and the use
More information54 Journal of Pain and Symptom Management Vol. 38 No. 1 July 2009
54 Journal of Pain and Symptom Management Vol. 38 No. 1 July 29 Special Article Improving Efficiency and Value in Palliative Care with Net Benefit Regression: An Introduction to a Simple Method for Cost-
More informationTHE FIRM AND ITS GOALS. Dr. Mohammed Alwosabi
CHAPTER TWO THE FIRM AND ITS GOALS Dr. Mohammed Alwosabi 1 The Firm The firm is an organization, which brings resources together to produce a good or service that is demanded in the market. The firm bears
More information